Assessment of the Efficacy of the Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Daily Headache in Children and Adolescents. — SPG

Post-Traumatic Headache Clinical Trial

Official title:
Efficacy of Transnasal Sphenopalatine Ganglion Block Using TX360® Device for Children and Adolescents With Chronic Daily Headaches: A Single Center, Prospective, Randomized, Double Blind, Placebo-controlled Study Assessing the Efficacy of the Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Daily Headache in Children and Adolescents

Status Not yet recruiting

Clinical Trial Summary

Primary Objective The primary objective of the study is to assess whether transnasal sphenopalatine ganglion block using the device TX360 reduces intensity and severity of the Post-Traumatic Headache in adolescents. Secondary Objectives The study will also evaluate: - Quality of life (QoL) - Intensity of the headache - Physical function - Sleep quality - Role function (measured by PEDMIDAS) - Adverse events

Clinical Trial Description

The sphenopalatine ganglion (SPG) is a large network of neurons that is easily accessible through the middle turbinate. The SPG is composed of branches from V1 and V2 of the trigeminal nerve and interconnects with sympathetic and parasympathetic autonomic fibers.6 The SPG has been successfully targeted transnasally to treat headache disorders and associated autonomic symptoms in adults.7 SPG blockade has been used in adults for treating several headache and facial pain conditions such as migraine, cluster headache, and trigeminal neuralgia.8 To our knowledge, there has not been any similar study done in children and adolescents. The Tx360® device (Tian Medical Inc., Lombard, IL, USA) allows for noninvasive blockade of the SPG using a small catheter below the middle turbinate of the nose that is administered just beyond the pterygopalatine fossa. Regarding the efficacity of Tx360®, recent studies show that repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device was well-tolerated and effective at decreasing baseline headache intensity in adults.6 ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05213065
Study type	Interventional
Source	McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact	Marie Vigouroux
Phone	5144124448
Email	marie.Vigouroux@mail.mcgill.ca
Status	Not yet recruiting
Phase	N/A
Start date	February 5, 2022
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04369729` - Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Completed	`NCT03588364` - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine	N/A
Recruiting	`NCT05378074` - Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache	N/A
Recruiting	`NCT05328635` - Post-traumatic Headache Multidisciplinary Study
Completed	`NCT04776304` - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms	N/A
Recruiting	`NCT04614922` - Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms	N/A
Recruiting	`NCT05595993` - Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache	N/A
Completed	`NCT03674398` - Aerobic Exercise and Cognitive Training Effects on Postconcussive Symptomology	N/A
Completed	`NCT02965027` - Prazosin for Post-Concussive Headaches	Phase 4
Active, not recruiting	`NCT05635656` - Digital Solutions for Concussion	N/A
Recruiting	`NCT06015451` - Exercise in Postconcussion Symptoms and Posttraumatic Headache	N/A
Recruiting	`NCT04906603` - Theta Burst Stimulation for Headaches After Traumatic Brain Injury	N/A
Terminated	`NCT01053507` - Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction	Phase 4
Completed	`NCT02419131` - Cognitive-Behavior Therapy for Posttraumatic Headache	N/A
Terminated	`NCT03806985` - Effects of Psilocybin in Concussion Headache	Phase 1
Completed	`NCT05243953` - Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache	N/A
Completed	`NCT03056352` - Metoclopramide for Post-Traumatic Headache. A Pilot Study	Phase 1/Phase 2
Recruiting	`NCT06132529` - A Study to Evaluate Biomarker Signature to Predict the Persistence of Post-traumatic Headache
Completed	`NCT01854385` - Sumatriptan as Treatment for Post-traumatic Headache	Phase 2
Completed	`NCT03523923` - TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.